1. Scrip
  2. >>Business

Takeda Looks To The New As It Braces For Velcade Generics

 
• By Ian Haydock

Takeda is facing major revenue challenges from US generics to its big seller Velcade, but is looking to successor and other new products to more than plug the gap.

Two businessmen pulling a rope, closeup shot tug of war
GENERIC VELCADE CHALLENGES LOOM IN US • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd. is bracing for “significant penetration of generic product” for its blockbuster multiple myeloma drug Velcade (bortezomib) in the US, particularly with the advent of the first such competitors in a subcutaneous formulation.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

In Brief: Sanofi Gains €10bn From Opella Sale

 
• By Sushmita Panda

Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.

Finance Watch: Biohaven Gains Up To $600m In Fresh Capital

 
• By Mandy Jackson

Public Company Edition: Biohaven secured $250m up front from Oberland Capital to support its future US troriluzole launch after pulling its EU filing. Also, Procaps arranged $130m in private equity and Rezolute grossed $96.9m in a rare follow-on offering, among other financings.

Lilly’s Ricks Urges Trump To Pick Tax Incentives Over Tariffs

 
• By Alaric DeArment

On Lilly’s Q1 earnings call, CEO David Ricks voiced concerns about the Trump Administration’s tariff policy, which he said could adversely affect Lilly and the industry as a whole.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

More from Scrip